International Biotechnology (LON:IBT) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?

International Biotechnology (LON:IBT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 684.42 ($8.37) and traded as high as GBX 703.25 ($8.60). International Biotechnology shares last traded at GBX 702 ($8.59), with a volume of 145,383 shares trading hands.

International Biotechnology Stock Down 0.3 %

The company's fifty day simple moving average is GBX 695.23 and its 200-day simple moving average is GBX 684.54. The firm has a market capitalization of £258.72 million, a PE ratio of 1,458.33 and a beta of 0.21. The company has a debt-to-equity ratio of 9.66, a current ratio of 0.46 and a quick ratio of 0.32.

International Biotechnology Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, January 24th. Stockholders of record on Thursday, December 19th will be given a GBX 15.56 ($0.19) dividend. This is a boost from International Biotechnology's previous dividend of $14.50. The ex-dividend date of this dividend is Thursday, December 19th. This represents a dividend yield of 2.21%. International Biotechnology's dividend payout ratio (DPR) is presently 6,041.67%.

Insider Activity at International Biotechnology

In related news, insider Katherine Cornish-Bowden bought 1,500 shares of the company's stock in a transaction on Tuesday, December 17th. The shares were bought at an average price of GBX 713 ($8.72) per share, with a total value of £10,695 ($13,085.77). 4.18% of the stock is currently owned by corporate insiders.

International Biotechnology Company Profile

The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.